Company overview
Current narrative, program map, milestone history, transaction objective and approved external materials
Owner · CEO / IRBiotech IPO field guide · Evidence architecture
Build the evidence room
before the filing room
A biotech IPO data room is not one checklist assembled at the end of the process. It is a controlled evidence system that follows the company from discovery through clinical development, financing, partnering and SEC review
Workstreams09
Stage views04
Reader lanes05
Editorial modelSource-led
01 · The nine-workstream blueprint
One evidence map from discovery to IPO
The folder names can vary. The control questions should not. Each workstream needs an owner, a current source set, a review status and a visible update trigger
Financials & cap table
Historical financials, burn, runway, capitalization, funding history, projections and use of proceeds
Owner · CFOLegal & IP
Corporate records, patent families, ownership, licenses, material contracts, disputes and obligations
Owner · GC / IP counselR&D / preclinical / clinical
Mechanism, platform, protocols, study reports, safety evidence, deviations and data provenance by program
Owner · CSO / CMORegulatory
Submission history, agency correspondence, meeting minutes, information requests, designations and strategy
Owner · RegulatoryCMC / manufacturing / quality
Process development, batch history, validation, stability, QMS, deviations, CAPA and supplier obligations
Owner · Tech ops / QualityCommercial & market
Indication sizing, competitive landscape, access assumptions, partnerships, launch model and dependencies
Owner · CommercialTeam & governance
Leadership, board oversight, scientific advisers, committees, incentives, key-person exposure and hiring plan
Owner · CEO / GCIPO disclosure controls
S-1 support, risk-factor evidence, disclosure owners, diligence requests, comment responses and version history
Owner · CFO / GC02 · Stage depth
Keep the map. Deepen the proof
The most common failure is rebuilding the room for each transaction. A durable evidence system preserves the same structure and changes the depth and access by stage
StageWorkstreams that deepenPrimary readersHardest probes
Discovery / preclinicalLegal & IP · platform · preclinicalSeed / Series A investors · grant reviewersMechanism · patent families · GLP toxicology
Phase 1–2Clinical · regulatory · CMC fundamentalsCrossover investors · pharma BDProtocols · safety · interim analyses · IND history
Phase 3 / registrationRegulatory · validation-grade CMC · commercialAcquirers · bankers · late-stage partnersFull CSRs · batch records · NDA/BLA readiness
IPO drafting / SEC reviewFinancials · governance · disclosure controlsBankers · counsel · auditors · boardRisk factors · S-1 support · comments · controls
03 · Reader lanes
One source set, different questions
Do not duplicate the underlying record for each audience. Control what each reader can see and maintain a single source of truth behind the views
Financial investors
Runway, capitalization, IP ownership, clinical inflections, use of proceeds and downside cases
Pharma BD
Program data, regulatory history, CMC, IP scope, license obligations and technical diligence trail
IPO bankers
Equity story, comparables, offering structure, diligence status and disclosure support
Counsel & auditors
Corporate authority, material contracts, financial support, consistency checks and review history
Board & regulators
Governance, safety oversight, agency correspondence, controlled records and accountable decisions
04 · Operating controls
The folder tree is not the control system
Evidence owner
Every material claim and workstream has a named business owner, not just a storage location
Status and version
Draft, final, superseded and exploratory materials are distinguishable without opening every file
Audience boundary
Reviewers receive only the program, financial and transaction depth appropriate to their role
Update trigger
Database changes, study milestones, regulatory correspondence, board actions and draft disclosures trigger review
Review history
Access, approvals, questions, responses and material changes remain reconstructable throughout the process
Editorial boundary This page maps evidence workstreams, not software suitability. The data-room selection guide describes documented provider use cases and discloses this site's commercial interest
05 · Questions and answers
Common questions about the evidence room
What belongs in a biotech IPO evidence room?
Nine workstreams: company overview, financials and capitalization, legal and intellectual property, research and clinical evidence, regulatory history, manufacturing and quality, commercial planning, team and governance, and IPO disclosure controls. The folder names can vary between companies. The control question behind each workstream should not, because that question is what every reviewer is actually testing.
How should the evidence room change by clinical stage?
Keep the same workstream map and deepen the evidence. Discovery companies emphasize mechanism and intellectual property; Phase 1 and 2 companies deepen clinical, regulatory and manufacturing evidence; registration-stage companies add full study reports, validation-grade manufacturing evidence and launch planning; IPO preparation adds audited financials, governance and disclosure support. Rebuilding the structure for each transaction is the most common and most expensive mistake.
Is a biotech IPO data room the same as an evidence room?
They describe different scopes. A data room is the controlled space opened for one transaction and closed when it ends. An evidence room is the durable system the company maintains across financing rounds, partnerships and the offering, from which each transaction room is populated. Companies that only build transaction rooms reassemble the same evidence from scratch every time.
Who should be able to see the whole evidence room?
Very few people, and usually only internally. Reviewers receive the program, financial and transaction depth appropriate to their role rather than the entire record, and a single underlying source set sits behind those views. Duplicating the record for each audience is how versions drift apart and how the wrong file reaches the wrong reader.
06 · Field guides
Take the blueprint to a specific transaction
This page describes the architecture. Each guide below works the same nine workstreams from the point of view of one reviewer and one decision
07 · Primary sources
Anchor claims to public records
A credible evidence room separates company-supplied records from public-source validation. These systems provide the common external backbone
Offering disclosure
S-1 and S-1/A filings, exhibits, EFFECT notices, 424B4 prospectuses and issuer correspondence. A quarterly archive of recent life-sciences filings shows these documents in use
EDGAR APIs ↗Trial record
Study phase, status, enrollment, endpoints, sponsor, locations and result availability
ClinicalTrials.gov API ↗Regulatory record
Drug approvals, labels, device pathways, safety communications and public regulatory databases
FDA databases ↗